ADEX
9.9.2019 16:55:11 CEST | Business Wire | Press release
HH Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs and International Cooperation and Deputy Chairman of the Board of Directors at Abu Dhabi Fund for Development (ADFD), announced the launch of the Abu Dhabi Exports Office (ADEX).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190909005676/en/
Established by ADFD, ADEX aims to support the national economy and enhance its competitiveness through the provision of financing and guarantees to overseas buyers from the public and private sectors seeking to import goods and services from the UAE. ADEX also aspires to contribute to raising the volume of national exports and facilitate entry into new markets. In addition to boosting national exports, ADEX aims to manage accompanying trade risks.
Highlighting the UAE’s top ranking across multiple global economic indicators, HH Sheikh Mansour bin Zayed Al Nahyan, Deputy Prime Minister, Minister of Presidential Affairs and Chairman of ADFD’s Board of Directors noted that to maintain its distinguished status, the country continues to explore new opportunities to grow its economic sectors, and increase the reach and volume of non- oil national exports.
HH Sheikh Abdullah bin Zayed Al Nahyan emphasised that the inception of ADEX represents a monumental leap in the implementation of the UAE’s economic diversification policies, boosting the national economy and reducing dependence on oil as a source of income.
Mohammed Saif Al Suwaidi, Director General of ADFD, said: “In line with the ambitious initiatives and plans of the UAE leadership, such as the UAE Vision 2021, Abu Dhabi Economic Vision 2030 and UAE Centennial 2071, Adhering to global best practices, ADEX seeks to expand the variety of UAE-made products and services for export, and raise the volume of national exports through providing financing and guarantee facilities.”
“In parallel with its role of supporting developing countries to achieve sustainable development through the allocation of concessionary loans, ADFD also contributes to the long-term prosperity of our nation through offering investment opportunities for national and private sector companies in the country and abroad.”
ADEX’s financing ratio holds the potential to reach 100%, depending on the type of funding and the nature of each transaction and the associated risks. To be eligible for financing, the products and services must be of UAE origin and meet creditworthiness requirements. The financing does not apply to crude-oil exports.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005676/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cegid Closes Acquisition of Shine to Create Europe's First Complete AI-Driven Platform for SMBs and Accountants8.6.2026 09:28:00 CEST | Press release
Accelerates Cegid’s trajectory to become the leading European financial solutions hub integrating e-invoicing, accounting, digital finance, payment services and accounts, and HR solutionsTransaction supported by new €1.1 billion debt financing facility secured from leading direct credit funds, underscoring Cegid’s strong business performance and unique leadership positioning in rapidly evolving software sector Cegid, a European leader in cloud management solutions for professionals in the finance (treasury, tax, ERP), human resources (payroll, talent management), accountancy, retail and entrepreneurship sectors, today announced the completion of its acquisition of Shine. The transaction creates the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe. Shine – a fast-growing European fintech unicorn providing electronic invoicing, accounting, business accounts, and payroll software to small and medium-sized businesses across Eu
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom